Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;10 Suppl 2(Suppl 2):S41-S47.
doi: 10.1002/sctm.20-0481.

Optimizing allogeneic grafts in hematopoietic stem cell transplantation

Zheng-Li Xu  1 , Xiao-Jun Huang  1
Affiliations
Review

Optimizing allogeneic grafts in hematopoietic stem cell transplantation

Zheng-Li Xu et al. Stem Cells Transl Med. 2021 Nov.

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely used in the treatment of hematological diseases. It is well known that allogeneic grafts play a key role in predicting transplantation prognosis. Hematopoietic stem cells (HSCs) are a functional part of grafts and are capable of reconstructing hematopoiesis and immunity, but purified HSCs have not been identified or isolated to date. In clinical practice, allogeneic grafts have been optimized to improve transplantation outcomes. The optimized grafts are considered to engraft successfully, reconstruct immunity rapidly, and exert a graft-vs-leukemia (GVL) effect without causing severe graft-vs-host disease (GvHD). In the last several decades, considerable efforts have been made in searching for optimized grafts based on different graft manipulation approaches and different graft sources. Currently, there is no uniform standard for optimized grafts in allogeneic transplantation. In the future, sorting out the cellular elements responsible for the effects of allo-HSCT might be a research direction for further optimization of grafts. In this review, we propose the concept of optimized grafts and summarize the recent advances made in the process of optimizing grafts.

Keywords: CD34+; hematologic malignancies; hematopoiesis; hematopoietic stem cell transplantation; hematopoietic stem cells.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest.

References

    1. Wang Y, Liu QF, Xu LP, et al. Haploidentical versus matched‐sibling transplant in adults with Philadelphia‐negative high‐risk acute lymphoblastic leukemia: a biologically phase III randomized study. Clin Cancer Res. 2016;22(14):3467‐3476. 10.1158/1078-0432.CCR-15-2335. - DOI - PubMed
    1. Xu LP, Jin S, Wang SQ, et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry‐based comparison with matched related transplant. J Hematol Oncol. 2017;10(1):25. 10.1186/s13045-017-0398-y. - DOI - PMC - PubMed
    1. Chang YJ, Xu LP, Wang Y, et al. Controlled, randomized, open‐label trial of risk‐stratified corticosteroid prevention of acute graft‐versus‐host disease after Haploidentical transplantation. J Clin Oncol. 2016;34(16):1855‐1863. 10.1200/JCO.2015.63.8817. - DOI - PubMed
    1. Jurecic R. Hematopoietic stem cell heterogeneity. Adv Exp Med Biol. 2019;1169:195‐211. 10.1007/978-3-030-24108-7_10. - DOI - PMC - PubMed
    1. Impola U, Larjo A, Salmenniemi U, et al. Graft immune cell composition associates with clinical outcome of allogeneic hematopoietic stem cell transplantation in patients with AML. Front Immunol. 2016;7:523. 10.3389/fimmu.2016.00523. - DOI - PMC - PubMed

Publication types